The Role of Myo-Inositol in the Management of Metabolic and Reproductive Sequelae of Polycystic Ovary Syndrome: A Comprehensive Review of the Current State of Knowledge
DOI:
https://doi.org/10.12775/QS.2026.51.68504Keywords
PCOS, Myo-inositol, Insulin Resistance, Oocyte Quality, Hyperandrogenism, 40:1 MI:DCI RatioAbstract
Polycystic Ovary Syndrome (PCOS) represents a heterogeneous and multifaceted endocrinopathy, characterized by extensive metabolic implications, affecting a substantial global cohort of reproductive-age women. Central to its pathogenesis is insulin resistance (IR) and compensatory hyperinsulinemia, which drive both metabolic dysfunction and reproductive failures. Myo-inositol (MI), acting as a vital second messenger for both insulin and follicle-stimulating hormone (FSH), has emerged as a cornerstone therapeutic agent. This comprehensive review evaluates the clinical efficacy of MI, particularly when administered in the physiological 40:1 ratio with D-chiro-inositol (DCI). We analyze its impact on glycemic profiles, hormonal stabilization, and the enhancement of oocyte competence. Based on the 2023 International Evidence-based Guidelines and recent clinical trials, MI represents a safe, well-tolerated, and effective alternative to traditional pharmacological interventions, providing a holistic approach to PCOS management.
References
Akbari Sene, A., Saeedzarandi, M., Moradi, Y., et al. (2025). Effect of myo-inositol supplementation on ICSI outcomes among poor ovarian responder patients: A randomized controlled trial. International Journal of Reproductive BioMedicine, 23(5). https://doi.org/10.18502/ijrm.v23i5.19260
Cantelmi, T., Lambiase, E., Unfer, V. R., Gambioli, R., & Unfer, V. (2021). Inositol treatment for psychological symptoms in Polycystic Ovary Syndrome women. European Review for Medical and Pharmacological Sciences, 25, 2383-2389. https://doi.org/10.26355/eurrev_202103_25409
Choudhari, R., Tayade, S., Tiwari, A., & Satone, P. (2024). Diagnosis, Management, and Associated Comorbidities of Polycystic Ovary Syndrome: A Narrative Review. Cureus, 16(4), e58733. https://doi.org/10.7759/cureus.58733
Cowan, S., Lim, S., Alycia, C., et al. (2023). Lifestyle management in polycystic ovary syndrome - beyond diet and physical activity. BMC Endocrine Disorders, 23, 14. https://doi.org/10.1186/s12902-022-01208-y
Fitz, V., Graca, S., Mahalingaiah, S., et al. (2024). Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines. The Journal of Clinical Endocrinology & Metabolism, 109, 1630-1655. https://doi.org/10.1210/clinem/dgad762
Lete, I., Martínez, A., Lasaga, I., Centurión, E., & Vesga, A. (2024). Update on the combination of myo-inositol/d-chiro-inositol for the treatment of polycystic ovary syndrome. Gynecological Endocrinology, 40(1), 2301554. https://doi.org/10.1080/10.1080/09513590.2023.2301554
Lentini, G., Querqui, A., Monti, N., & Bizzarri, M. (2024). PCOS and Inositols - Advances and Lessons We are Learning. A Narrative Review. Drug Design, Development and Therapy, 18, 1181–1196. https://doi.org/10.2147/DDDT.S524718
Mei, Y., Li, W., Wang, B., et al. (2025). Gut microbiota an emerging target connecting polycystic ovarian syndrome and insulin resistance. Frontiers in Cellular and Infection Microbiology, 15, 1508893. https://doi.org/10.3389/fcimb.2025.1508893
Oszukowski, P., Jakimiuk, A., Spaczyński, M., et al. (2022). Position statement of the Expert Group of the Polish Gynecological Society on the use of myo-inositol in patients with polycystic ovary syndrome (PCOS). [Article in Polish]. https://journals.viamedica.pl/ginekologia_polska/article/view/45928/32719
Pajtel, K., & Pelczyńska, M. (2019). The use of inositol in the light of the latest scientific research. Selected Clinical Problems, 34-40. [Article in Polish].
https://journals.viamedica.pl/forum_leczenia_otylosci/article/view/90249/66957
Pustotina, O., Myers, S. H., Unfer, V., & Rasulova, I. (2024). The Effects of Myo-Inositol and D-Chiro-Inositol in a Ratio 40:1 on Hormonal and Metabolic Profile in Women with Polycystic Ovary Syndrome Classified as Phenotype A by the Rotterdam Criteria and EMS-Type 1 by the EGOI Criteria. Gynecologic and Obstetric Investigation, 89, 131-139. https://doi.org/10.1159/000536163
Radomski, D., & Jarząbek-Bielecka, G. (2019). The myoinositol in the treatment of girls with PCOS - preliminary analysis. Pediatric Endocrinology, 18(1), 37-44. [Article in Polish] https://doi.org/10.18544/EP-01.18.01.1715
Roseff, S., & Montenegro, M. (2020). Inositol Treatment for PCOS Should Be Science-Based and Not Arbitrary. International Journal of Endocrinology, 6461254. https://doi.org/10.1155/2020/6461254
Sharon, P. M., Mellonie, P., Manivannan, A., Thangaraj, P., & Logeswari, B. M. (2024). The Effectiveness of Myo-Inositol in Women With Polycystic Ovary Syndrome: A Prospective Clinical Study. Cureus, 16(2), e53951. https://doi.org/10.7759/cureus.53951
Szkodziak, P., & Paszkowski, T. (2012). The effect of myo-inositol treatment on insulin resistance in patients with polycystic ovary syndrome in a 3-month observation. e-medycyna.pl. [Article in Polish]. https://inofem.pl/wp-content/uploads/2022/03/Inofem-Badanie-kliniczne.pdf
Teede, H. J., Tay, C. T., Laven, J. J., et al. (2023). Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. European Journal of Endocrinology, 189, G43-G64. https://doi.org/10.1093/ejendo/lvad096
Unfer, V., Facchinetti, F., Orrù, B., Giordani, B., & Nestler, J. (2017). Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials. Endocrine Connections, 6, 647-658. https://doi.org/10.1530/EC-17-0243
Wdowiak, A., & Filip, M. (2020). The effect of myo-inositol, vitamin D3 and melatonin on the oocyte quality and pregnancy in in vitro fertilization: a randomized prospective controlled trial. European Review for Medical and Pharmacological Sciences, 24, 8529-8536. https://www.europeanreview.org/wp/wp-content/uploads/8529-8536.pdf
Wdowiak, A. (2016). Myoinositol improves embryo development in PCOS patients undergoing ICSI. International Journal of Endocrinology, 2016, 6273298. https://doi.org/10.1155/2016/6273298
Zhang, J., Zhang, H., Zhou, W., Jiang, M., & Lin, X. (2025). Effect of myo-inositol supplementation in mixed ovarian response IVF cohort: a systematic review and meta-analysis. Frontiers in Endocrinology, 16, 1520362. https://doi.org/10.3389/fendo.2025.1520362
Zhao, H., Xing, C., Zhang, J., & He, B. (2021). Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis. Reproductive Health, 18, 171. https://doi.org/10.1186/s12978-021-01207-7
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Agnieszka Irena Bullmann, Julia Baran, Karolina Wojciechowska, Ewelina Choroszewska, Wiktor Warych, Julia Niezgoda, Tomasz Skłodowski, Katarzyna Woroniecka
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 4
Number of citations: 0
